Vertex Pharmaceuticals Incorporated (VRTX) fair value analysis
S&P 500 · Updated 2026-10-19
VRTX price how computed
Forward Fair Value verdict
Fairly valuedVRTX is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $510.08
- Sector
- Healthcare
- 12-month range
- $409.47–$557.96
- Market cap
- $129B
- From 52-week high
- -8.6%
- Shares outstanding
- 253M
- Rank in Healthcare by discount to fair value
- #70 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Vertex Pharmaceuticals Incorporated is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases including cystic fibrosis, pain, and viral infections. The company operates globally with research and development facilities and commercial operations across multiple regions including North America, Europe, and other international markets.
VRTX currently ranks #70 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 4 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $129B
- P/E (trailing)
- 28x
- Revenue (TTM)
- $12.6B
- Net margin
- 34.9%
- EPS (TTM)
- $18.50
- Gross margin
- 85.3%
- Debt / equity
- 0.10
- Revenue growth (3-yr avg)
- 11.4%
- Shares outstanding
- 253M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 44 · neutral
- 50-day average
- $522.54
- 200-day average
- $475.90
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-02 (post-market)
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+1.2%)
2026-03 ▲ beat (+3.8%)
2025-12 ▼ miss (-2.3%)
2025-09 ▲ beat (+4.8%)
2025-06 ▲ beat (+6.4%)
2025-03 ▼ miss (-5.4%)
2024-12 ▼ miss (-1.0%)
2024-09 ▲ beat (+6.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 26 buy · 4 hold · 2 sell (32 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $571
- Target vs last price
- +11.9%
What our data shows for VRTX
- Our model validated 13 trailing price-to-earnings windows for VRTX, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $409.47–$557.96.
- The 14-day relative strength index sits at a neutral 44.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for VRTX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent VRTX news
TickrTrends' derived news-sentiment signal for VRTX is currently leaning positive, computed from recent coverage.
- Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial (insidermonkey.com, 2026-10-12)
TickrTrends take: Vertex Pharmaceuticals operates in the competitive Healthcare sector where clinical trial progression and pipeline advancement are key drivers of long-term value. While this headline concerns a different company's trial, it reflects ongoing activity in rare disease development that affects the broader therapeutic landscape where Vertex competes. Given Vertex's current Fairly valued assessment, investors should monitor how developments in comparable pipeline programs influence market expectations for similar therapeutic areas and clinical timelines. - Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets (insidermonkey.com, 2026-10-03)
TickrTrends take: Vertex operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends metrics. The comparison to Regeneron highlights different competitive positioning within biotech, where investors must evaluate the durability and breadth of each company's pipeline and intellectual property advantages. For valuation-focused readers, tracking how Vertex's pipeline advancement and market exclusivity developments progress will be important to monitoring whether the fairly valued assessment remains appropriate relative to peers. - Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)? (insidermonkey.com, 2026-09-29)
TickrTrends take: Vertex Pharmaceuticals operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends metrics. The company's advancement in kidney disease treatment represents a potential expansion of its addressable market, which could become relevant to valuation reassessment if the breakthrough translates into material revenue contributions. Investors focused on valuation should monitor whether this therapeutic progress leads to meaningful commercial adoption and financial impact sufficient to justify any future price movements.
What people are saying
Follow the VRTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — VRTX moved up 6 positions in its sector discount ranking this week, from number 91 to number 85 among Healthcare stocks. The stock's valuation verdict improved from Overvalued to Fairly valued based on TickrTrends' derived indicators. This shift reflects a more balanced relationship between VRTX's current price and its fundamental metrics relative to peers in the Healthcare sector.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for VRTX have shifted this week, with the valuation verdict improving from Overvalued to Fairly valued. This change reflects a recalibration of the company's current market valuation relative to its fundamental metrics within the Healthcare sector. The stock's assessment now suggests it is appropriately priced based on the indicators tracked by TickrTrends.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is VRTX stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), VRTX is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is VRTX's TickrTrends verdict?
VRTX's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does VRTX compare to other Healthcare stocks?
VRTX ranks #70 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is VRTX overbought or oversold?
VRTX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does VRTX report earnings next?
VRTX's next earnings report is scheduled for 2026-11-02 (post-market), per the published earnings calendar.
Does VRTX usually beat earnings estimates?
Over its last 8 reported quarters VRTX beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about VRTX?
Of 32 analysts covering VRTX, 26 rate it a buy, 4 a hold and 2 a sell - buy-leaning, with a consensus price target of $571 (+11.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
VRTX vs ACAD · VRTX vs ASND · VRTX vs BIIB · VRTX vs BMY · VRTX vs BVS